C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells

Effects and mechanisms of resveratrol for prevention and management of cancers: An updated review

(2022) Si-Xia Wu et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

(2022) Govinda Poudel et al.   Cancers

MEK inhibitors for the treatment of non-small cell lung cancer

(2021) Jing Han et al.   Journal of Hematology & Oncology

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

(2021) Sarah K. Madden et al.   Molecular Cancer

Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c‐Myc axis on panobinostat cytotoxicity

(2021) Sara Zehtabcheh et al.   CELL BIOLOGY INTERNATIONAL

Autophagy-related signaling pathways are involved in cancer (Review)

(2021) Caixia Chen et al.   Experimental and Therapeutic Medicine

The long journey to bring a Myc inhibitor to the clinic

(2021) Jonathan R. Whitfield et al.   JOURNAL OF CELL BIOLOGY

Epigenetic Silencing of MYC By Proteasome Inhibitors

(2021) Andre Catic et al.   BLOOD

Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes

(2021) Roya Ghaffarnia et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

(2021) Raquel Alves et al.   Cancers

Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance

(2020) Mohammad Mosleh et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Targeting autophagy to overcome drug resistance: further developments

(2020) Haocai Chang et al.   Journal of Hematology & Oncology

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?

(2020) Simona Soverini et al.   Journal of Clinical Medicine

MYC Oncogene Contributions to Release of Cell Cycle Brakes

(2019) Lucía García-Gutiérrez et al.   Genes

Suppression of c‐Myc using 10058‐F4 exerts caspase‐3‐dependent apoptosis and intensifies the antileukemic effect of vincristine in pre‐B acute lymphoblastic leukemia cells

(2019) Negar Sheikh‐Zeineddini et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat

(2019) Ida Annunziata et al.   Nature Communications

Proteasome inhibition in multiple myeloma: lessons for other cancers

(2019) Paula Saavedra-García et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

(2016) Sheela A. Abraham et al.   NATURE

Small-molecule inhibitors of the Myc oncoprotein

(2015) Steven Fletcher et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma

(2015) Meng Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts

(2015) Q Li et al.   CANCER GENE THERAPY

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

(2015) Munevver Cinar et al.   LEUKEMIA RESEARCH

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

(2015) Toril Holien et al.   Oncotarget

NF-κB1 inhibits c-Myc protein degradation through suppression of FBW7 expression

(2015) Haishan Huang et al.   Oncotarget

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells

(2014) Jiandong Wang et al.   Journal of Translational Medicine

Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors

(2014) Inga Müller et al.   PLoS One

Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells

(2014) ITASU NINOMIYA et al.   Oncology Letters

MYC Activation Is a Hallmark of Cancer Initiation and Maintenance

(2014) M. Gabay et al.   Cold Spring Harbor Perspectives in Medicine

Myc inhibition impairs autophagosome formation

(2013) Pearl P. C. Toh et al.   HUMAN MOLECULAR GENETICS

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

(2012) Charles Y. Lin et al.   CELL

c-Myc and Cancer Metabolism

(2012) D. M. Miller et al.   CLINICAL CANCER RESEARCH

GADD45 Proteins: Central Players in Tumorigenesis

(2012) R. E. Tamura et al.   CURRENT MOLECULAR MEDICINE

Phosphoinositide 3-kinase/AKT/mTORC1/2 Signaling Determines Sensitivity of Burkitt's Lymphoma Cells to BH3 mimetics

(2012) L. C. Spender et al.   MOLECULAR CANCER RESEARCH

Akt, FoxO and regulation of apoptosis

(2011) Xinbo Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib

(2011) M. Albajar et al.   MOLECULAR CANCER RESEARCH

Chronic Myeloid Leukemia: A Historical Perspective

(2010) John M. Goldman   SEMINARS IN HEMATOLOGY

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

(2009) Zheng Hu et al.   PLoS One

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

(2008) Jianxia Guo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FOXOs, cancer and regulation of apoptosis

(2008) Z Fu et al.   ONCOGENE